Key result
Rasburicase administration for the prevention and treatment of chemotherapy-induced hyperuricemia resulted in a 100% response rate and significant reductions in uric acid levels (P<0.001).
Why the study?
Does rasburicase reduce or maintain safe uric acid levels in pediatric and adult cancer patients at risk for tumor lysis syndrome?
Population
278 patients with cancer at risk for tumor lysis syndrome during the initiation of chemotherapy…
Design
Cohort
Follow-up
24-48 hours after administration of the last dose
Authors
Loading...
Supports rasburicase in chemotherapy-induced hyperuricemia; leaves open randomized confirmation before changing tumor lysis syndrome practice.
Observational (n=278)
Yes
Does rasburicase reduce or maintain safe uric acid levels in pediatric and adult cancer patients at risk for tumor lysis syndrome?
p-value: p=<0.001
Rasburicase is highly effective and safe for the prevention and treatment of chemotherapy-induced hyperuricemia in both pediatric and adult cancer patients.
Bosly et al. (2003) conducted an observational in Hyperuricemia and tumor lysis syndrome in cancer patients (n=278). Rasburicase was evaluated on Reduction in uric acid level or maintenance of a level <7.5 mg/dL (or <6.5 mg/dL for children <13 years) (p=<0.001). Rasburicase administration for the prevention and treatment of chemotherapy-induced hyperuricemia resulted in a 100% response rate and significant reductions in uric acid levels (P<0.001).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: